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Abstract
Aberrant gluconeogenic gene expression is associated with diabetes, glycogen storage disease, and liver cancer. However,
little is known how these genes are regulated at the chromatin level. In this study, we investigated in HepG2 cells whether
histone demethylation is a potential mechanism. We found that knockdown or pharmacological inhibition of histone
demethylase LSD1 causes remarkable transcription activation of two gluconeogenic genes, FBP1 and G6Pase, and
consequently leads to increased de novo glucose synthesis and decreased intracellular glycogen content. Mechanistically,
LSD1 occupies the promoters of FBP1 and G6Pase, and modulates their H3K4 dimethylation levels. Thus, our work identifies
an epigenetic pathway directly governing gluconeogenic gene expression, which might have important implications in
metabolic physiology and diseases.
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Introduction
Hepatic glucose production is essential for maintaining blood
glucose homeostasis, which ensures a steady fuel supply for many
cell types in the body. Hepatic glucose production is accomplished
by two processes, initially via glycogenolysis that breaks down
glycogen in the first few hours after a meal, and subsequently via
gluconeogenesis that de novo synthesizes glucose from non-
carbohydrate precursors during prolonged fasting. Uncontrolled
gluconeogenesis is a major contributor to hyperglycemia in both
type 1 and type 2 diabetes [1,2,3]. While gluconeogenesis runs in
the opposite direction of glycolysis and shares several reverse
enzymatic reactions with glycolysis, three steps, catalyzed by a
separate set of key enzymes, phosphoenolpyruvate carboxykinase
(PEPCK), fructose-1,6-bisphosphatase (FBP1) and glucose 6-
phosphatase (G6Pase), are non-reversible and largely determine
the rate of gluconeogenesis. G6Pase additionally catalyzes the
terminal step in the glycogenolytic pathway. Deficiency in G6Pase
in patients results in glycogen storage disease Ia (GSD Ia),
exhibiting hypoglycemia and abnormal hepatic accumulation of
glycogen [4].
These key gluconeogenic enzymes are also suggested to play
potentially important roles in suppression of liver carcinogenesis.
Dramatic decrease of PEPCK, FBP1 and G6Pase gene expression
was observed in hepatocellular carcinoma (HCC) developed in a
mouse model and in the majority of primary human HCCs [5]. A
separate study showed that FBP1 promoter is hypermethylated at
the CpG sites in primary human HCCs and HCC cell lines, which
results in their lower FBP1 expression relative to normal cells [6].
Importantly, restoration of FBP1 expression inhibits cancer cell
proliferation [6]. In patients with G6Pase mutations (GSD1a),
hepatocellular adenomas are the most severe complication with a
75% prevalence; 10% of them eventually transform to HCC
[7,8,9,10]. Similarly, liver-specific G6Pase knockout mice develope
hepatocellular adenomas [11]. These results indicate suppressive
functions of FBP1 and G6Pase in hepatocarcinogenesis. While the
underlying mechanism remains obscure, reduction of FBP1 level
might lead to a higher concentration of its substrate fructose-1,6-
bisphosphate, which is an allosteric activator of glycolytic enzyme
pyruvate kinase. Thus, a higher concentration of fructose-1,6-
bisphosphate would in turn causes increased aerobic glycolysis, a
process that is essential for cancer cell growth. Alternatively,
downregulation of G6Pase is likely to increase the concentration of
its substrate glucose-6-phosphate, which can be used by pentose
phosphate shunt pathway to produce ribose-5-phosphate for
nucleotide synthesis, as has been alluded [5]. Indeed, it has been
observed that transformation of hepatocytes to cancer cells is
usually associated with a reduction in gluconeogenesis, an
activation of the glycolytic pathway and the pentose phosphate
shunt pathway [12].
Given the roles of these key gluconeogenic enzymes in diabetes,
glycogen storage disease and tumorigenesis, their transcriptional
regulation have been explored extensively. These studies identified
a number of transcription factors (e.g., CREB, FOXO1, FOXA2,
C/EBPs, HNF4a, GR, Nur77, and RORa) and co-activators (e.g.,
PGC-1a, CRTC2, SIRT1, p300/CBP, SRC-1, and SRC-2)
[13,14] that assemble on the well-defined PEPCK and G6Pase
promoters [15,16,17,18] to drive their gene expression. Chromatin
regulation is another fundamental process controlling gene
expression. One study reported that the level of histone H3
arginine 17 dimethylation at the PEPCK promoter correlates with
PEPCK gene expression [19]. We recently showed that histone
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demethylase Jhdm1a indirectly suppresses the expression of
PEPCK and G6Pase through demethylation of H3 lysine 36
(H3K36) at the C/EBPa locus [20]. Clearly, our current
understanding of gluconeogenic gene expression at the chromatin
level is very rudimentary.
LSD1 is the first histone demethylase identified [21]. LSD1
associates with CoREST, CtBP and NuRD co-repressor com-
plexes [22,23,24] and demethylates monomethyl- and dimethyl-
H3 lysine 4 (H3K4) of its target genes [21], thereby leading to
transcriptional repression. LSD1 was shown to function in diverse
processes such as stem cell renewal and differentiation, embryonic
and organ development, and carcinogenesis
[24,25,26,27,28,29,30]. Here, we identify LSD1 as a key negative
regulator of FBP1 and G6Pase expression and reveal a direct
epigenetic mechanism underlying gluconeogenesis.
Results
Knockdown of LSD1 promotes FBP1 and G6Pase
expression in human HepG2 cells and in primary mouse
hepatocytes
As discussed above, abnormal gluconeogenic gene expression
not only causes metabolic diseases but also contributes to
hepatocarcinogenesis. We investigated whether these genes are
controlled epigenetically. We performed our studies in HepG2
cells, as many known transcriptional pathways regulating gluco-
neogenic gene expression are retained in this HCC cell line. We
generated two human LSD1 shRNA knockdown constructs and
packaged them into lentiviruses. We infected HepG2 cells with the
knockdown and scramble control viruses at a similar number of
viral particles. We found that both LSD1 knockdown constructs
significantly promoted the expression of FBP1 and G6Pase mRNA
that were correlated with the LSD1 knockdown efficiency (Figure
1A). We typically observed a more than 5-fold induction of FBP1
and G6Pase expression in the first knockdown construct, which
resulted in an increase of FBP1 and G6Pase protein levels.
Interestingly, PEPCK expression was not affected by LSD1
knockdown (Figure 1A). This is in contrast to our previous
findings that knockdown of histone demethylase Jhdm1a increased
the expression of PEPCK and G6Pase but not FBP1 [20]. Thus,
gluconeogenic genes can be differentially regulated by multiple
histone demethylases.
Because G6Pase also catalyzes the terminal step of glycogen-
olysis, we examine whether LSD1 regulates the expression of
additional enzymes in this pathway. Knockdown of LSD1 had no
effect on the expression of glycogen debranching enzyme (amylo-
alpha-1, 6-glucosidase, 4-alpha-glucanotransferase, AGL) and
glucose-6-phosphate transporter (G6PT) (Figure 1B). The expres-
sion of Glut2, which transport glucose out of hepatocytes, was also
not changed. Thus, LSD1 regulates only a subset of genes in the
gluconeogenic and glycogenolytic pathways.
We next carried out LSD1 overexpression experiments via
lentiviral infection. Overexpression of wild type LSD1 did not
affect the expression of G6Pase in HepG2 cells, indicating that
endogenous LSD1 level is not a limiting factor. Indeed,
endogenous LSD1 protein was abundant and readily detectable
in these cells by western blotting analysis (Figure 1A). On the other
hand, overexpression of a LSD1 point mutant (K666A), which
abolishes its demethylation activity [27,31], leads to a reproducible
increase of G6Pase expression (Figure 1C), indicating a dominant
negative effect, as would be expected. These data provide further
evidence for the role of LSD1 in suppression of gluconeogenic
gene and indicate a requirement of its demethylation activity.
We addressed whether regulation of gluconeogenic gene
expression occurs in normal hepatocytes. We infected mouse
primary hepatocytes with lentiviruses expressing a mouse LSD1
knockdown construct. Despite that LSD1 was only knocked down
by 50%, a derepression of FBP1 and G6Pase expression was
observed (Figure 1D). Therefore, LSD1-mediated suppression of
gluconeogenic gene expression is not limited to liver cancer cells,
and might have a physiological relevance.
Pharmacological inhibition of LSD1 phenocopies the
effects of LSD1 knockdown on gluconeogenic gene
expression
Tranylcypromine (TCP) potentially inhibits the demethylation
activity of LSD1 [32,33]. We treated HepG2 cells with TCP and
analyzed gene expression. FBP1 and G6Pase, but not G6PT, were
robustly induced by TCP treatment at all three indicated time
points (Figure 2). The rapid response to TCP treatment suggests
that FBP1 and G6Pase might be direct target genes of LSD1.
PEPCK was slightly increased during prolonged TCP treatment;
this increase is probably indirect, as it was not seen in either LSD1
knockdown or 6 hr TCP treatment. Thus, the LSD1 inhibitor
recapitulates the role of LSD1 knockdown for gluconeogenic gene
expression.
LSD1 regulates glucose production in vitro
To determine whether suppression of gluconeogenic gene
expression by LSD1 has a functional consequence, we cultured
LSD1 knockdown HepG2 cells in a medium that contains
gluconeogenic substrates for 6 hr and measured de novo glucose
synthesis. As shown in Figure 3A, knockdown of LSD1 signifi-
cantly promoted glucose synthesis. Similar results were obtained
when cells were treated with the LSD1 inhibitor TCP (Figure 3B).
Because G6Pase also catalyzes the terminal step of glycogenolysis,
we suspect that increased expression of G6Pase by LSD1
knockdown might result in diminished intracellular glycogen level.
To test this, we first cultured HepG2 cells in a high glucose
medium to allow glycogen accumulation. Cells were then shifted
to a medium without glucose for 4 hr. Intracellular glycogen was
isolated and assayed. We found that glycogen content was
significant lower in LSD1 knockdown cells (Figure 3C). Our data
suggest that LSD1 negatively regulates both gluconeogenesis and
glycogenolysis, at least in vitro.
LSD1 associates with gluconeogenic gene promoters
We investigated how LSD1 represses gluconeogenic gene
expression. Previous work by others has shown that Nur77,
Nor1 and transcriptional co-activator Src-2 upregulate G6Pase
but not PEPCK expression [34,35], similar to what we observed
for LSD1 knockdown. However, knockdown of LSD1 had no
effect on the levels of Nur77, Nor1 and Src-2 (Figure 4A). We also
did not observe an increase of other transcriptional regulators
important for both PEPCK and G6Pase expression, such as PGC-
1a and C/EBPa. These results, together with the rapid induction
by TCP, raise the possibility that LSD1 directly represses FBP1
and G6Pase expression. To test this idea, we performed chromatin
immunoprecipitation (ChIP) assays in HepG2 cells to determine
whether endogenous LSD1 protein is located at their promoters.
As shown in Figure 4B, LSD1 was detected at both FBP1
promoter region (2214 to 2119 bp) and G6Pase promoter region
(2242 to 2131 bp). These regions have been shown to interact
with several transcription factors [6,17,18,36,37]. Thus, LSD1
occupies the FBP1 and G6Pase promoters, likely through its
interaction with transcription factors.
LSD1 Suppresses Gluconeogenic Gene Expression
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Both knockdown and inhibition of LSD1 increase the
levels of H3K4me2 at gluconeogenic gene promoters
H3K4 dimethylation (H3K4me2) peaks around transcriptional
start sites and its level positively correlates with gene expression
[38]. Given the association of LSD1 with the FBP1 and G6Pase
promoters, we performed ChIP assays to examine whether LSD1
regulates the dynamics of H3K4 methylation in HepG2 cells.
H3K4 at both FBP1 and G6Pase promoters are dimethylated
(Figure 5A and B), consistent with the idea that the two genes are
active or poised for activation in HepG2 cells. Knockdown of
LSD1 elevated the levels of H3K4me2 at the two promoters
(Figure 5A). TCP treatment produced a similar effect (Figure 5B).
These results support a model that LSD1 directly demethylates
H3K4me2 at FBP1 and G6Pase promoters and that induction of
FBP1 and G6Pase expression by LSD1 knockdown or inhibition is
due to an increase of H3K4me2 levels.
Discussion
FBP1 and G6Pase genes play important roles in gluconeogen-
esis, glycogen mobilization, and liver tumorigenesis. Their
expression levels are tightly controlled by an array of transcription
factors and co-factors [13,14]; however, little is known how they
are regulated by the chromatin landscape. Here, we identify LSD1
Figure 1. LSD1 regulates FBP1 and G6Pase expression in cultured hepatic cells. (A, B) LSD1 was knocked down in HepG2 cells with shRNA
lentiviruses. Gene expression (n = 3–4) was determined with quantitative real-time PCR. Full names of individual genes and QPCR primers used are
listed in Table 1. Right panel in (A), protein levels analyzed by western blot. (C) Lentiviral overexpression of LSD1 point mutant (K666A) increases
G6Pase expression in HepG2 cells. Middle panel, G6Pase levels in HepG2 cells treated with a combination of dibutyryl cyclic-AMP (cAMP, 0.5 mM) and
dexamethasone (Dex, 1 mM) for 6hr. Right panel, protein levels analyzed by western blot. Experiments were repeated three times with similar results.
(D) Gene expression in mouse primary hepatocytes with LSD1 knockdown (n= 2). *, P,0.05; **, P,0.01.
doi:10.1371/journal.pone.0066294.g001
LSD1 Suppresses Gluconeogenic Gene Expression
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as a key epigenetic regulator that directly modulates the expression
of FBP1 and G6Pase. Knockdown or pharmacological inhibition
of LSD1 causes an increase of H3K4me2 levels at FBP1 and
G6Pase promoters and an upregulation of their expression,
resulting in enhanced glucose synthesis and diminished intracel-
lular glycogen accumulation. Our data suggest that the dynamic
H3K4me2 marker is important for proper gluconeogenic gene
expression and that LSD1-mediated demethylation is a potentially
important epigenetic mechanism underlying the gluconeogenic
process. However, it should be noted that this mechanism was
revealed through in vitro cell culture studies and its relevance to in
vivo physiology and pathophysiology remains to be validated with
animal models. If our findings can be extended to in vivo studies, it
raises a possibility for a potential utility of LSD1 inhibitors in the
treatment of a variety of forms of G6Pase-independent glycogen
storage diseases and hepatocellular carcinoma.
Table 1. Gene full names and primersequences used in this study.
Gene full name Sequences for shRNA, QPCR and CHIP assays
shRNA target sequence
LSD1 lysine (K)-specific demethylase 1A GCCTAGACATTAAACTGAATA (human, construct 1)
GCTCCAATACTGTTGGCACTA (human, construct 2)
GGATGGGATTTGGCAACCTT (mouse)
Primers used for real-time QPCR
LSD1 lysine (K)-specific demethylase 1A F: TCCCTTAAGCACTGGGATCA (human)
R: CCACAGGCACACACGAGTAG (human)
F: GCCTGTTTCCCAGACATCAT (mouse)
R: CAGCTGGATCTTTGGGTTGT (mouse)
FBP1 fructose-1,6-bisphosphatase 1 F: CCCCAGATAATTCAGCTCCTTA (human)
R: GTTGCATTCGTACAGCAGTCTC (human)
F: GGATTGTGGTGTCAACTGCTT (mouse)
R: AGTCCTTGGCATAACCCTCAT (mouse)
G6Pase glucose-6-phosphatase, catalytic subunit F: GGGAAAGATAAAGCCGACCTAC (human)
R: CAGCAAGGTAGATTCGTGACAG (human)
F: AAGCCAACGTATGGATTCCG (mouse)
R: ACAGCAATGCCTGACAAGACT (mouse)
PEPCK phosphoenolpyruvate carboxykinase 1 (soluble) F: TGACAACTGCTGGTTGGCT
R: TGGTGCGACCTTTCATGC
AGL amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase F: GGATGGGTAATGGGAGATGA
R: TAACACTGTCTCCCCAGCAA
G6PT solute carrier family 37 (glucose-6-phosphate
transporter), member 4
F: CCATGTACCTCTTCCGGGTA
R: GCCATACGAGGAGAAACCAA
GLUT2 solute carrier family 2 (facilitated glucose transporter),
member 2
F: ATGTGGCTCAGCAATTTTCC
R: CCAACTCCAATGGTTGCATA
NUR77 nuclear receptor subfamily4, group A, member 1 F: CACAGCTTGCTTGTCGATGT
R: GGTTCTGCAGCTCCTCCA
NOR1 nuclear receptor subfamily4, group A, member 3 F: CACCTTCTCCTCCAATCTGC
R: GCCTGGTCAGTGGGACAGTA
SRC-2 nuclear receptor coactivator 2 F: GCACAAACGAAGAGCAAACTC
R: CCATCGTTTGTCCAGTCAGAT
PGC-1a peroxisome proliferator-activated receptor gamma,
coactivator 1 alpha
F: CACAGTCGCAGTCACAACACT
R: TTCCACACTTAAGGTGCGTTC
C/EBPa CCAAT/enhancer binding protein (C/EBP), alpha F: TGGACAAGAACAGCAACGAGTA
R: ATTGTCACTGGTCAGCTCCAG
b-actin actin, beta F: CCTGGCACCCAGCACAAT
R: GCCGATCCACACACGGAGTACT
U36B4 ribosomal protein, large, P0 F: AGATGCAGCAGATCCGCA
R: GTTCTTGCCCATCAGCACC
CHIP assays primers
FBP1 promoter 21293,21166
promoter 2214,2119
F: TCTCCAGTGGGTTCCTCCTA
R: ACCGGTGGAGCTGAAATAGA
F: CAGCCCAGGAAGACTAGGG
R: GCCTGCTTGGATCTTCAGAC
G6Pase promoter 2242,2132
promoter 2150,258
F: CCAAGAAGCATGCCAAAGTT
R: TGCAAACATGTTCAGGGTGA
F: CACCCTGAACATGTTTGCAT
R: AGCCCTGATCTTTGGACTCA
GAPDH 59UTR 4432631 F: CGGCTACTAGCGGTTTTACG
R: AAGAAGATGCGGCTGACTGT
doi:10.1371/journal.pone.0066294.t001
LSD1 Suppresses Gluconeogenic Gene Expression
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In contrast to H3K36 demethylase Jhdm1a, which indirectly
regulates PEPCK and G6Pase expression through demethylation
of C/EBPa locus [20], several lines of evidence support a direct
role of LSD1 for the suppression of FBP1 and G6Pase expression.
First, we found no increase of mRNA levels of known gluconeo-
genic transcriptional regulators upon LSD1 knockdown, although
we can not rule out the possibility that any of the factors might be
a non-histone substrate for LSD1; second, induction of FBP1 and
G6Pase in response to TCP treatment is very rapid; third, LSD1
occupies FBP1 and G6Pase promoters and knockdown or
inhibition of LSD1 leads to an increase of H3K4me2 levels at
these promoters. However, the detailed mechanism of how LSD1
is recruited to these promoters and represses their transcription
remains to be determined. Interestingly, LSD1 is located at a NF-
Figure 2. Induction of gluconeogenic gene expression by LSD1 inhibitor TCP. HepG2 cells were treated with 1 mM TCP or DMSO. Total
RNA was extracted at indicated time and gene expression was examined with QPCR, n = 3. Right panel, protein levels at indicated time were analyzed
by western blot.
doi:10.1371/journal.pone.0066294.g002
Figure 3. LSD1 regulates glucose production in HepG2 cells. Assays were performed as described in Materials and Methods. (A, B)
gluconeogenesis in LSD1 knockdown cells (A) or in cells pre-treated with TCP for 16 hr (B), n = 4. (C) glycogen content in LSD1 knockdown cells, n = 3.
*, P,0.05; **, P,0.01.
doi:10.1371/journal.pone.0066294.g003
LSD1 Suppresses Gluconeogenic Gene Expression
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kB-binding site on the FBP1 promoter. Studies have shown that
activation of NF-kB results in DNA methylation of this promoter
and consequently FBP1 expression silencing [6,37]. As demeth-
ylation of H3K4 appears to be a prerequiste for DNA methylation
[39], one testable model is that LSD1 is recruited to the FBP1
promoter by NF-kB, and then elicits DNA hypermethylation
through removal of H3K4me2. This model might also involve the
NR4A orphan nuclear receptor members. NR4A members
regulate FBP1 and G6Pase expression, but not PEPCK expression
[34]. NR4A members have also been shown to recruit LSD1-
CoREST complex to NF-kB target gene promoters to suppress
their expression [40]. Thus, these studies indicate a possible
molecular connection among LSD1, NF-kB and NR4A members
that governs FBP1 and G6Pase gene expression. Further studies
are necessary to elucidate whether and how LSD1 coordinates
with these factors and other epigenetic modifiers in the gluconeo-
genic process.
Our studies raise several mechanistic questions that warrant
investigation. For example, what is the opposing histone methyl-
transferase(s) that methylates H3K4 at the FBP1 and G6Pase
promoters? What other components in the LSD1-associated co-
repressor complexes are required for gluconeogenic gene repres-
sion? How is LSD1-mediated demethylation at the FBP1 and
G6Pase promoters regulated in response to physiological cues and
disease states? Answering these questions in the future will provide
important insights into the epigenetic control of glucose metab-
olism and its impacts in diseases.
Materials and Methods
Cell cultures
HepG2 cells (ATCC, # HB-8065) were grown in DMEM
medium (Invitrogen #11965-092) with 10% fetal bovine serum
(Atlanta Biologicals #s11150), 100 U/ml penicillin and 10 mg/ml
streptomycin. Primary mouse hepatocytes were prepared and
cultured as described previously [20,41].
Lentiviral knockdown
LSD1 knockdown or scramble oligonucleotides were inserted
into pSP108 lentiviral vector (Addgene). Lentiviral particles were
produced in 293T cells. HepG2 cells in 6-well plates were infected
with a similar number of viral particles. Cells were transferred into
10-cm culture dishes next day and selected with 2 mg/ml
puromycin for three days. Cells were then re-plated into 12-well
plates at a similar confluency and cultured in the presence of
puromycin for two more days.
Lentiviral overexpression
Mouse wild-type and point mutant LSD1 coding sequence were
cloned into pENTR-1A vector and recombined with plenti-
CMV/neo plasmid to generate lentiviral constructs. The lentivirus
was generated as described previously [20]. HepG2 cells were
transduced with similar number of viral particles, selected with
2 mg/ml G418 and cultured as above.
TCP treatment
HepG2 cells were plated into 6-well plates. At 80% confluency,
cells were treated with DMSO or 1 mM trans-2-phenylcyclopro-
pylamine hydrochloride (TCP, sigma #P8511). mRNA or protein
levels were determined.
Gluconeogenic assay
Cells were treated with 0.5 mM dibytyryl cyclic-AMP (cAMP)
and 1 mM dexamethasone (Dex, 1mM) for 5 hr. Cells were then
washed 3 times with PBS and incubated in glucose/phenol-red
free DMEM medium containing 2 mM sodium pyruvate and
20 mM sodium lactate for 6 hr. Glucose levels in the medium were
measured with an Amplex red glucose assay kit (Invitrogen,
#A22189).
Glycogen content
HepG2 cells were incubated with high glucose (50 mM)
DMEM medium for 2 hr, and then shifted to glucose-free DMEM
medium for 4 hr. The glycogen contents in the cells were
measured as published with minor modification [42]. Briefly, after
washed 3 times with PBS, the cells were collected in 50 mM
sodium acetate (pH4.5) and lysed by sonication on ice. The
supernatants of the disruptants were incubated at 55uC for 1hr in
the absence or presence of amyloglucosidase (200 mU/ml, sigma
#A7420). After the reaction, the samples were deproteinized,
neutralized and the glucose levels were measured with an Amplex
red glucose assay kit. The glycogen contents were calculated by
Figure 4. LSD1 associates with FBP1 and G6Pase promoters. (A)
LSD1 was knocked down in HepG2 cells with shRNA lentiviruses.
Expression levels of gluconeogenic regulators were examined, n = 324.
(B) LSD1 associates with FBP1 and G6Pase promoters. Data were shown
from one representative of two independent experiments with similar
results.
doi:10.1371/journal.pone.0066294.g004
LSD1 Suppresses Gluconeogenic Gene Expression
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subtracting the glucose levels of the undigested samples from those
of the digested samples.
Western Blotting
Cells were collected in lysis buffer [100 mM NaCl, 50 mM Tris
(pH 7.5), 0.5% Triton X-100, 5% (w/v) glycerol] with protease
inhibitor tablets (Roche) and PMSF, and incubated on ice for 30
min. The lysates were cleared by centrifugation at 16,000 g for 10
min at 4uC. Equal amounts of protein sample were then separated
on 8% SDS polyacrylamide gels. Antibodies against LSD1
(Abcam#ab17721), FBP1 (Abgent #AP7385C), G6Pase (Santa
Cruz #sc-25840), PEPCK (ABcam #ab28455) and b-tubulin
(DSHB #E7-S) were used.
RNA isolation and real time quantitative PCR
Total RNA was isolated using Trizol (Invitrogen) following
manufacturer’s instructions and was subjected to reverse tran-
scription with SuperScript III Reverse Transcriptase (Invitrogen
#18080-044). Real time quantitative PCR was performed using
reagent iTaq SYBR Green Supermix with ROX (Bio-rad #172-
5850). All the signals were normalized with b-actin or U36B4 and
the 22DDCT method was used for quantification.
Chromatin immunoprecipitation assays
HepG2 cells on 10-cm dishes (16107 cells/dish) were fixed in
1% formaldehyde for 5 min at room temperature. Cells were
washed with cold PBS containing protease inhibitor cocktail
(Roche) and pelleted by centrifugation. The cell pellets were
suspended in ChIP lysis buffer (50 mM Tris-HCl pH 8.1, 10 mM
Figure 5. Regulation of H3K4me2 at FBP1 and G6Pase promoters by LSD1. HepG2 cells were infected with LSD1 knockdown lentiviruses (A)
or treated with TCP (1 mM) (B), and H3K4me2 levels were examined at FBP1, G6Pase and GAPDH promoters. All data were shown from one
representative of two independent experiments with similar results.
doi:10.1371/journal.pone.0066294.g005
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EDTA, 1% SDS and protease inhibitors). Fragmentation of the
DNA (100–200bp) was achieved by a 50 sec sonication (10 sec
pulse on and 5 sec pulse off) on ice with ultrasonic processor (Cole
Parmer) at 40% amplitude. The sheared chromatin was cleared by
centrifugation at 16,000 g for 10 min at 4uC and diluted 10-fold in
CHIP IP buffer (16.7 mM Tris-HCl pH 8.1, 1.2 mM EDTA,
1.1% Triton X-100, 0.01% SDS, 167 mM NaCl). 50% protein A-
sepharose slurry (GE Healthcare #17-0780-01) was added to the
sample and incubated for 1 hr at 4uC with rotation. The pre-
cleared chromatin samples were then immunoprecipitated with
antibodies against LSD1 (5 mg, Abcam #ab17721), dimethyl-
H3K4 (5 mg, Millipore#07-030) or normal rabbit IgG (Sigma#I-
5006). Two percent of the chromatin samples were saved as input
control. DNA samples from the CHIP were purified with PCR
purification kits (Qiagen) and applied for quantification by real
time PCR. CHIP signal was normalized with input signal.
Statistical analysis
Student’s t test (two-tailed) was used for statistical analysis.
P,0.05 was considered significant. Data are presented as mean 6
s.e.m.
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